Fatal pneumonitis after treatment with docetaxel and trastuzumab

Netherlands Journal of Medicine

Volumn 67, Issue 6, 2009, Pages 237-239

  Kuip, E ^a   Muller, E ^a  

^a SLINGELAND HOSPITAL   (Netherlands)

Author keywords

Docetaxel; Pneumonitis; Pulmonary toxicity

Indexed keywords

CEFTAZIDIME; DOCETAXEL; TRASTUZUMAB; VANCOMYCIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TAXOID;

ADULT; ANAMNESIS; ARTICLE; AUTOPSY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; FEBRILE NEUTROPENIA; FEMALE; FIBROSING ALVEOLITIS; HOSPITAL DISCHARGE; HUMAN; LABORATORY TEST; PHYSICAL EXAMINATION; PNEUMONIA; RESPIRATORY FAILURE; THORAX RADIOGRAPHY; CHEMICALLY INDUCED; FATALITY; MIDDLE AGED; RESPIRATORY INSUFFICIENCY; RISK FACTOR;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; FATAL OUTCOME; FEMALE; HUMANS; MIDDLE AGED; PNEUMONIA; RESPIRATORY INSUFFICIENCY; RISK FACTORS; TAXOIDS;

EID: 68149156221     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Read W, Mortimer J, Picus J. Severe interstitial pneumonitis associated with docetaxel administration. Cancer. 2002;94:847-853 (Pubitemid 34132316)
2. Mileshkin L, Prince H, Rischin D, Zimet A. Severe interstitial pneumonitis following high-dose cyclophosphamide, thiotepa and docetaxel: two case reports and a review of the literature. Bone Marrow Transplant. 2001;27:559-563 (Pubitemid 32266510)
3. Wang G, Yang K, Perng R. Life threatening hypersensitivity pneumonitis induced by docetaxel (taxotere). Br J Cancer 2001; 85:1247-1250 (Pubitemid 33081915)
4. Etienne B, Perol M, Nesme P, Vuillernoz S, Robinet G, Guiren J. Pneumopathie interstitielle diffuse aigue sous docetaxel. A propos de 2 observations. Rev Mal Respir 1998;15:199-203. (Pubitemid 28213050)
5. Dunsford M, Mead G, Bateman A, Cook T, Tung K. Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transition cell carcinoma. Ann Oncol. 1999;10:943-947 (Pubitemid 29424574)
6. Merad M, Lecesne A, Baldeyrou P, Mesurolle B, Lechevalier T. Docetaxel and interstitial pulmonary injury. Ann Oncol 1997;.8:191-194 (Pubitemid 27112889)
7. Rossi S, Erasmus J, McAdams P, Sporn T, Goodman P. Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics. 2000;5:1245-1259
8. Radzikowska E, Szczepulska E, Chabowski M, Bestry I. Organising pneumonia caused by trastuzumab (herceptin) therapy for breast cancer. Eur Respir J. 2003;21:552-555 (Pubitemid 36336219)
9. Vahid B, Mehrotra A. Trastuzumab (herceptin)-associated lung injury. Respirology. 2006;11(5):655-658
10. Kourossis C, Mavroudis D, Kakolyris S, et al. High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small-cell lung cancer: results of a dose-finding study. Lung Cancer. 2004;44:363-368 (Pubitemid 38609445)
11. Nasser H, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier oncology group and U.S oncology. J Clin Oncol. 2008;26:5755-5760
12. Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer. Phase II Southwest Oncology Group Study S9504. J Clin Oncol. 2003;21:2004-2010 (Pubitemid 46606390)
13. Grande C, Villanueva M, Huidobro G, Casal J. Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment. Clin Transl Oncol. 2007;9:578-581
14. Vento S, Cainelli F, Temesgen Z. Lung infections after cancer chemotherapy. Lancet Oncol. 2008;9:982-992